0001209191-23-059814.txt : 20231227 0001209191-23-059814.hdr.sgml : 20231227 20231227172640 ACCESSION NUMBER: 0001209191-23-059814 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20231222 FILED AS OF DATE: 20231227 DATE AS OF CHANGE: 20231227 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Hohl Benjamin CENTRAL INDEX KEY: 0001882764 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39247 FILM NUMBER: 231518879 MAIL ADDRESS: STREET 1: 6200 LOOKOUT ROAD CITY: BOULDER STATE: CO ZIP: 80301 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Enliven Therapeutics, Inc. CENTRAL INDEX KEY: 0001672619 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 6200 LOOKOUT ROAD CITY: BOULDER STATE: CO ZIP: 80301 BUSINESS PHONE: 720-647-8519 MAIL ADDRESS: STREET 1: 6200 LOOKOUT ROAD CITY: BOULDER STATE: CO ZIP: 80301 FORMER COMPANY: FORMER CONFORMED NAME: IMARA Inc. DATE OF NAME CHANGE: 20160419 4 1 doc4.xml FORM 4 SUBMISSION X0508 4 2023-12-22 0 0001672619 Enliven Therapeutics, Inc. ELVN 0001882764 Hohl Benjamin C/O ENLIVEN THERAPEUTICS, INC. 6200 LOOKOUT ROAD BOULDER CO 80301 0 1 0 0 Chief Financial Officer 1 Common Stock 2023-12-22 4 M 0 1030 2.48 A 1030 D Common Stock 2023-12-22 4 S 0 1030 15.0728 D 0 D Common Stock 2023-12-26 4 M 0 100 2.48 A 100 D Common Stock 2023-12-26 4 S 0 100 15.00 D 0 D Employee Stock Option (right to buy) 2.48 2023-12-22 4 M 0 1030 0.00 D 2031-08-02 Common Stock 1030 261090 D Employee Stock Option (right to buy) 2.48 2023-12-26 4 M 0 100 0.00 D 2031-08-02 Common Stock 100 260990 D The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. This transaction was executed in multiple trades at prices ranging from $15.00 to $15.24. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. The option, originally for 262,120 shares, vested as to one-fourth of the shares vests on August 2, 2022, and the remainder of the shares vest in 36 equal monthly installments thereafter. /s/ Benjamin Hohl 2023-12-27